Armed forces quelling terror, oppn seeking proof: PM Modi

The government suspended all the India-bound air travel from China and has declared all visas 'invalid', on Monday, due to the rapid escalation of cases of novel coronavirus outbreak which originated in Wuhan.

"Embassy and our Consulates have been receiving several queries from Chinese citizens as well as other foreign nationals, who are based out of China or visited China in the last 2 weeks, as to whether they can use their valid single/multiple entry visas to travel to India," tweeted the Embassy of India in Beijing, China.

"It is clarified that existing visas are no longer valid. Intending visitors to India should contact the Indian Embassy in Beijing ([email protected]) or the Consulates in Shanghai ([email protected]) and Guangzhou ([email protected]) to apply afresh for an Indian visa," it said.

Further, regarding the validity of visas, the embassy said, "Indian Visa Application Centres (http://blsindia-china.com) in these cities may also be contacted in this regard. Visa Section of the Embassy/Consulates of India in China can be contacted to ascertain the validity of visa before undertaking any visit to India."

"All those who are already in India (with regular or e-visa) and had traveled from China after January 15 are requested to contact the hotline number of Ministry of Health and Family Welfare of Government of India (+91-11-23978046 and email: [email protected])," the embassy said.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

New Delhi, May 13: With an increase of 3,525 COVID-19 cases reported in the last 24 hours, India's tally of positive coronavirus cases rises to 74,281 cases, as of Wednesday, said the Ministry of Health and Family Welfare.

The tally is inclusive of 47,480 patients who are active coronavirus cases and 24,385 patients who have been cured/discharged and one patient migrated.

With an increase of 122 deaths due to COVID-19 reported in the last 24 hours, the number of deaths in the country now stands at 2,415.

According to the ministry, Maharashtra has the most number of positive COVID-19 cases with 24,427 positive cases that include 5,125 patients recovered and 921 fatalities.

Gujarat has reported 8,903 COVID-19 cases inclusive of 3,246 recovered patients and 537 deaths due to the coronavirus.

Tamil Nadu reported 8,718 positive coronavirus cases with 2,134 patients recovering from the disease and 61 succumbing to the infection.

Delhi's tally of COVID-19 cases stands at 7,639 cases with 2,512 patients recovering and 86 patients died due to coronavirus.

Meanwhile Arunachal Pradesh (one case reported--now recovered), Goa (seven cases reported--all seven recovered), Manipur (two cases reported--both recovered) and Mizoram (one case reported--now recovered) have reported no new cases of COVID-19.